Following a full submission considered under the orphan equivalent process:
nintedanib (Ofev®) is accepted for use within NHSScotland.
Indication under review: in adults for the treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype other than idiopathic pulmonary fibrosis (IPF).
Nintedanib, compared with placebo, slowed the decline in forced vital capacity (FVC) in adults with non-IPF progressive fibrosing ILD.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
- Medicine name:
- nintedanib (Ofev)
- SMC ID:
Treatment in adults of other chronic fibrosing interstitial lung diseases with a progressive phenotype.
- Pharmaceutical company
- Boehringer Ingelheim Ltd
- BNF chapter
- Respiratory system
- Submission type
- Date advice published
- 07 June 2021